Ed Mathers

Partner, NEA

Mr. Mathers has served as a member of our board of directors since 2016. Mr. Mathers has served as a General Partner at New Enterprise Associates (NEA), a private venture capital firm focusing on technology and healthcare investments, since 2019, and prior to that served as partner at NEA from 2008 to 2019. Prior to joining NEA, Mr. Mathers served as Executive Vice President, Corporate Development and Venture at MedImmune and led its venture capital subsidiary, MedImmune Ventures. Mr. Mathers currently serves on the board of directors of Affinia Therapeutics, Akouos, Amplyx Pharmaceuticals, Inozyme Pharma, MBX Biosciences, Mirum Pharmaceuticals, ObsEva SA, Reneo Pharmaceuticals, Rhythm Pharmaceuticals, Synlogic, (formerly known as Mirna Therapeutics) and Trevi Therapeutics.

Mr. Mathers earned his B.S. in Chemistry from North Carolina State University.